Mumbai, August 06, 2024: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2024. The unaudited results were taken on record by the Board of Directors at a meeting held today.
Income Statement Highlights – Q1 FY2025
v Gross Profit was INR 37,697 Mn compared to INR 33,213 Mn in Q4 FY2024, with gross margin of 68.4%.
v Personnel cost was 17.6% of sales at INR 9,710 Mn compared to INR 9,002 Mn in Q4 FY2024.
v Manufacturing and other expenses were at 29.0% of sales at INR 15,985 Mn compared to INR 14,901 Mn in Q4 FY2024.
v PBT was 18% at INR 9,930 Mn on account of better performance of Q1 FY2025 and an impairment charge of INR 2,013 Mn in Q4 FY2024.
v Investment in R&D for the quarter was INR 3,500 Mn (6.3% of sales).
Balance Sheet Highlights as on date June 30, 2024
- Operating working capital was INR 61,686 Mn.
- Capital Expenditure for the quarter was INR 1,117 Mn.
- Net Debt as on June 30, 2024 stands at INR (195) Mn.
- Net Debt-Equity as on June 30,2024 stands at 0.00.
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We have had a strong quarter on the back of the momentum we built through FY24, with performance driven by new products, key geographies, and improvement in our operating margin and profitability. We are on track for strong, sustainable growth and margin improvement backed by growth in sales, commercial and operating efficiencies, and a strong compliance story.”
